BSX (Boston Scientific) Total Stockholders Equity: $24,930 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSX Boston Scientific Corp BSX
77 GF Score
Price $50.37
GF Value $106.96
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Boston Scientific Total Stockholders Equity?

Boston Scientific BSX +2.03% 77 Total Stockholders Equity is $24,930 Mil as of Jun. 2026. GuruFocus rates BSX with a GF Score™ of 77/100 and a GF Value™ of $106.96 (Significantly Undervalued). The stock has 1 warning sign investors should review.

Boston Scientific's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $24,930 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Boston Scientific's Book Value per Share for the quarter that ended in Jun. 2026 was $17.23. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Boston Scientific's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.51.

Boston Scientific  (NYSE:BSX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Boston Scientific's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(24930-0)/1446.706
=17.23

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Boston Scientific's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1709 + 10915) / 24930
=0.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boston Scientific Total Stockholders Equity Related Terms

Boston Scientific Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Boston Scientific's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boston Scientific Total Stockholders Equity Chart

Boston Scientific Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16,623.00 17,574.00 19,281.00 21,770.00 24,232.00

Boston Scientific Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22,418.00 23,395.00 24,232.00 25,864.00 24,930.00
BSX
77GF Score
Boston Scientific Corp BSX
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $24,930 Mil mean?
Boston Scientific (BSX) has a Total Stockholders Equity of $24,930 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Boston Scientific and its competitors.
Is Boston Scientific's Total Stockholders Equity too high?
Boston Scientific's current Total Stockholders Equity is $24,930 Mil. Overall, Boston Scientific has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Boston Scientific's Total Stockholders Equity compare to EW and DXCM?
Boston Scientific's Total Stockholders Equity of $24,930 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Medical Devices & Instruments company?
A good Total Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Boston Scientific and its competitors. Boston Scientific's current Total Stockholders Equity is $24,930 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boston Scientific stock overvalued right now?
Based on GuruFocus' analysis, Boston Scientific (BSX) is currently considered Significantly Undervalued. The stock's GF Value™ is $106.96, compared to a current price of $50.37 — trading 52.9% below its estimated fair value. The current Total Stockholders Equity is $24,930 Mil. Boston Scientific's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Boston Scientific (BSX), the current Total Stockholders Equity is $24,930 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Boston Scientific (BSX) Overvalued in 2026?

Based on GuruFocus' analysis, Boston Scientific stock appears to be undervalued. The current stock price of $50.37 is trading 52.9% below its estimated GF Value™ of $106.96. GuruFocus considers Boston Scientific to be Significantly Undervalued.

Key valuation signals for BSX:

  • Total Stockholders Equity: $24,930 Mil
  • GF Value™: $106.96 vs. price of $50.37 (52.9% below fair value)
  • GF Score™: 77/100 with 1 warning sign

No single metric tells the full story. See the BSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Boston Scientific Business Description

Address 300 Boston Scientific Way, Marlborough, MA, USA, 01752-1234
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
77GF Score

Get the complete analysis for BSX

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$50.37
Price
$106.96
GF Value